Neurology Alert – September 1, 2005
September 1, 2005
View Issues
-
PML Complicating Treatment with Natalizumab (Tysabri) for MS
These 2 cases demonstrate a tragic complication of natalizumab therapy in this promising novel immune modulatory therapy, and the difficulties of predicting late stage drug failures in the difficult and costly process of drug development. -
Review: Treatment of Inflammatory Neuropathies
Neuropathies with IgM monoclonal gammopathy may respond to various chemotherapeutic agents, although the long-term effects are unknown. -
Genetic Predictors of AED Dosing
report provides evidence of a drug target polymorphism in epilepsy patients predictive of their maintenance dose of AEDs. -
Transient Ischemic Attack: Short-Term and Long-Term Risk Factor for Stroke
Patients who have had a transient ischemic attack have not only a high short-term chance of ischemic stroke but also a long-term risk of vascular events over 10 years or more. -
Fleur du Mal: IRIS in AIDS-Related PML
Better understanding of the mechanisms of the IRIS may enable prevention or cure of this severe, sometimes fatal complication of HAART. -
A New Cause of Treatment-Responsive Limbic Encephalitis
A new from of limbic encephalitis is reported, characterized by neuropil antibodies. Patients show an excellent response to immunotherapy or tumor resection. -
Pharmacology Watch: Beta-Blockers May Be Useful for Noncardiac Surgery
High-risk patients benefit from perioperative beta-blockers when undergoing major noncardiac surgery according to new study.